![](https://porib.com/wp-content/uploads/2021/07/revista_de_neurologia.jpg)
Sánchez-De la Rosa R, Sabater E, Casado MA
Análisis de Impacto presupuestario del tratamiento en primera línea de la esclerosis múltiple remitente recurrente en España
Rev Neurol. 2012;54:446-4474
![](https://porib.com/wp-content/uploads/2021/06/farmacia_hospitalaria.jpg)
Donoso Sanz MA, Díaz S, Oyagüez I, Casado MA
Impacto presupuestario de la utilización de hormona de crecimiento de la edad pediátrica a la adulta
Farm Hosp. 2012;36(1):1-3
![](https://porib.com/wp-content/uploads/2021/07/journal_of_medical_economics.jpg)
Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R
Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients
J Med Econ. 2012;15(3):1–10
Roldán C, del Castillo JC, Ramos F, Magaña A, Sabater E
Atrial Fibrillation in clinical practice in Spain. Comparison of the management among General Practitioners in the Canary Islands and the North of Spain
9th Annual Meeting of Health Technology Assessment International (HTAi). Bilbao, Spain. 25-27 jun 2012
González-Juanatey JR, Álvarez-Sabin J, Lobos JM, Martínez-Rubio A, Reverter JC, Oyagüez I, González-Rojas N, Becerra V
Economic evaluation of dabigatran etexilate in stroke prevention in patients with non valvular atrial fibrillation
21st European Stroke Conference (ESC). Lisbon, Portugal. 22-25 may 2012
Álvarez-Sabín J, Yébenes M, Mar J, Oliva J, Becerra V, Arenillas JF, Martínez-Zabaleta MT, Rebollo M, Segura T, Lago A, Gállego J, López-Gastón JI, Moniche F, Castillo J, Jiménez-Martínez MC, López-Fernández JC, Casado-Naranjo I, González-Rodríguez C, Escribano B, Casado MA, Masjuan J